Efficacy and clinicogenomic biomarkers of response to dual versus single agent checkpoint inhibitor therapy in untreated metastatic non-small cell lung cancer.
Authors: Daniel Boiarsky, Lingzhi Hong, Biagio Ricciuti, Alissa Jamie Cooper, Maliazurina B Saad, Arielle Elkrief, Alessandro Di Federico, Muhammad Aminu, Waree Rinsurongkawong, Jeff Lewis, Don Lynn Gibbons, Ara A. Vaporciyan, Xiuning Le, J. Jack Lee, John Heymach, Jia Wu, Adam Jacob Schoenfeld, Mark M. Awad, Jianjun Zhang, Natalie I Vokes
Journal: Journal of Clinical Oncology (2024)

8549 Background: Biomarkers to guide the application of CTLA-4 inhibitors with anti-PD-(L)1 in untreated EGFR/ALK-negative metastatic non-small cell lung cancer (mNSCLC) are underexplored. Methods: Patients with ECOG performance status 0-1 and untreated EGFR/ALK-negative mNSCLC who received dual immune checkpoint inhibitor (ICI) therapy, or single agent PD-(L)1 inhibitor alone (ICI-mono) or with chemotherapy (ICI-chemo) at three institutions were analyzed. Clinical progression-free survival (PFS), and overall survival (OS) were the primary outcomes. Patients with progressive disease (PD) or stable disease (SD) as per RECIST 1.1 were considered non-responders, whereas those with partial or complete response (PR/CR) were considered responders. Inverse propensity weighting (IPW) for clinical and sociodemographic characteristics was used to control for differences in treatment selection. To identify subgroups of patients who benefit from dual ICI therapy, we conducted IPW multivariate analysis, including clinico-genomic covariates alone and in interaction with treatment assignment. Results: A total of 2347 patients (48% female, median age 67; dual ICI 255, ICI-mono 789, ICI-chemo 1303) were included. In unadjusted analysis, as compared to ICI-mono or ICI-chemo, dual IC was associated with an increase in OS (ICI-mono: HR = 0.8, p = 0.011; ICI-chemo: HR = 0.7, p = 4.7e-05) and a relatively smaller increase in PFS (ICI-mono: HR = 0.8, p = 0.041; ICI-chemo: HR = 0.9, p = 0.076). Among responders who received dual vs ICI+/-chemo there was no difference in OS (dual ICI vs ICI-mono: HR = 1.0, p = 0.89; dual ICI vs ICI-chemo: HR = 0.7, p = 0.11), whereas there was an increase in OS among non-responders (dual-ICI vs ICI-mono: PD: HR = 0.7, p = 0.033; SD: HR = 0.8, p = 0.1; dual-ICI vs ICI-chemo: PD: HR = 0.5, p = 1.7e-06; SD: HR = 0.7, p = 0.033. On IPW-adjusted analysis among patients with complete clinical annotation (n=478), OS (ICI-mono: HR = 0.70, p = 0.03; ICI-chemo: HR = 0.60, p = 0.0051) but not PFS (ICI-chemo: HR = 1.0, p = 0.70; ICI-mono: HR = 0.80, p = 0.11) was increased in patients treated with dual vs ICI+/-chemo. In multivariate IPW analysis among patients with complete clinical and genomic annotation (n = 369), PFS was increased in dual ICI vs ICI-chemo treated patients with bone mets (HR = 0.34, p = 0.0029) and squamous histology (HR = 0.35, p = 0.0076). PFS was increased in dual ICI vs ICI-mono treated patients with bone mets (HR = 0.45, p = 0.041). Conclusions: In this retrospective cohort of patients with untreated mNSCLC, dual ICI therapy improved overall survival as compared to ICI+/-chemo among patients without, but not with, response to treatment. Dual ICI therapy increased time to progression in patients with bone mets and squamous histology. Further studies are warranted to develop an optimal treatment-selection strategy for untreated mNSCLC.